Full-Time

Sales and Partnerships Manager

Digital Diagnostics

Posted on 3/19/2025

PathAI

PathAI

201-500 employees

AI-powered pathology platform for diagnostics

No salary listed

Junior, Mid

Remote in Spain

Category
Sales Development Representative
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • 2-3 years of experience in business development, management consulting, and/or strategic partnerships, including at least 2-4 years experience in an operational, commercial, or sales role at a healthtech start-up or diagnostics company
  • Fluent in English and Spanish (required)
  • Ability to work in an international and cross-functional team, specifically willingness to collaborate with marketing, commercial, product development, strategic partnerships, and legal/regulatory teams
  • Willingness to travel up to 50% of the time
Responsibilities
  • Identify pathology laboratories that are ripe for digital pathology implementation and build relationships with key stakeholders across pathology, IT, and administrative functions.
  • Structure and execute deals with anatomic pathology laboratories and manage the end to end process including initial outreach, pitch/demo, technical discussions, RFP / tender processes, security approvals, contracting, negotiations, and implementation (including ensuring compliance with appropriate regulatory guidelines).
  • Introduce our digital diagnostic products to customers and elaborate their differentiation to customers in collaboration with marketing.
  • Seamlessly handoff relationship and account management to the respective account manager.
  • Identify pathways to unlock market and customers specific entry barriers and collaborate with a cross-functional team to overcome them.
  • Share insights from customers on new product features and improvements to further advance PathAI products and services, including local requirements unique to Spain and Portugal.
  • Proactively identify sales pipeline risks, develop mitigation plans, and adjust forecasts accordingly.
  • Support overall commercial strategy for a channel and/or geography-specific sales strategy by conducting segmentation analyses of anatomic pathology laboratories and key accounts based on company priorities.
Desired Qualifications
  • Fluent in Portuguese (preferred)
  • Experience presenting and/or selling to senior and enterprise-level executives in a healthcare or clinical diagnostic setting (preferred)
  • Experience in public procurement processes in Spain and Portugal (preferred)
  • Experience or deep interest in (diagnostic) medicine, biology, and pathology in particular (preferred)
  • Familiarity with software sales, healthtech product, artificial intelligence, anatomic pathology, and/or molecular diagnostics in Spain and/or Portugal (preferred)

PathAI focuses on improving patient outcomes by using an AI-powered pathology platform. This platform enhances the accuracy of medical diagnoses and the effectiveness of treatments for diseases like cancer through advanced machine learning techniques. PathAI provides diagnostic tools and services to healthcare providers, research institutions, and pharmaceutical companies, generating revenue through partnerships, licensing, and service fees. What sets PathAI apart from its competitors is its commitment to solving complex healthcare problems with a diverse team and a focus on making a significant impact in the medical field. The company's goal is to ensure better patient outcomes by leveraging technology in pathology.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$358.7M

Headquarters

Boston, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI's collaboration with Precision for Medicine enhances clinical trial services.
  • The launch of PathAssist Derm expands PathAI's reach in skin cancer diagnostics.
  • CE mark certification allows PathAI to enter the European diagnostic market.

What critics are saying

  • Over-reliance on AI could lead to diagnostic errors.
  • Rapid AI development may outpace regulatory frameworks.
  • High implementation costs may limit accessibility for smaller providers.

What makes PathAI unique

  • PathAI offers end-to-end automation for scalable pathology solutions.
  • The company focuses on AI-powered tools for accurate cancer diagnosis.
  • PathAI's AISight platform integrates advanced digital pathology capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive medical, dental, and vision insurance

Retirement plan options

Paid parental leave

Health & wellness benefits

Flexible work options

Generous paid time off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
PR Newswire
Apr 25th, 2025
Precision For Medicine And Pathai Announce Strategic Collaboration To Advance Ai-Powered Clinical Trial Services And Biospecimen Products

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discoveryBOSTON and FREDERICK, Md., April 25, 2025 /PRNewswire/ -- Precision for Medicine, a leading provider of next generation drug development research and services, and PathAI, a global leader in digital pathology, today announced a strategic collaboration to partner on developing novel AI-based technologies and to integrate PathAI's advanced digital pathology and analysis capabilities across Precision for Medicine's clinical trial and biospecimen operations. This collaboration includes use of several PathAI technologies and establishes an agreement to offer novel tools and analytical services that address emerging needs in biomarker discovery, spatial biology, and tissue-based clinical research. Through this collaboration PathAI's tools and services will help augment Precision for Medicine's proprietary pipeline providing biopharma clients with access to imaging workflows offered through Precision for Medicine's integrated laboratory and clinical trial services

Hit Consultant
Apr 25th, 2025
Precision For Medicine & Pathai Launch Strategic Ai Digital Pathology Partnership

Precision for Medicine PathAI Launch Strategic AI Digital Pathology Partnership. by Fred Pennic 04/25/2025 Leave a Comment. What You Should Know: – Precision for Medicine, a provider of next-generation drug development research and services, and PathAI, a global leader in digital pathology, announced a strategic collaboration today.– The partnership aims to jointly develop novel AI-based technologies and integrate PathAI’s advanced digital pathology and analysis capabilities across Precision for Medicine’s comprehensive clinical trial and biospecimen operations.AI-Powered Clinical Trial Services and Biospecimen ProductsAs part of the agreement, Precision for Medicine will deploy selected technologies from PathAI, including its AISight® digital pathology image management system and other AI-powered algorithms. These tools will enhance Precision for Medicine’s biospecimen analysis workflows by incorporating validated, algorithm-based quality control steps, thereby improving data consistency and reliability. PathAI’s capabilities will augment Precision for Medicine’s proprietary service pipeline, offering biopharma clients integrated imaging workflows accessible through Precision’s laboratory and clinical trial services.The collaboration will also leverage PathAI’s leading AI and machine learning models to enrich Precision for Medicine’s multi-modal datasets. This advanced technology facilitates the reduction of large, complex biomarker panels into scalable, actionable insights crucial for interpreting complex tissue biology

Hit Consultant
Feb 4th, 2025
Pathai Launches Pathassist Derm, An Ai-Powered Tool For Skin Lesion Analysis

What You Should Know:– PathAI, a provider of AI-powered pathology solutions, today announced the launch of PathAssist Derm, an innovative tool designed to streamline the analysis of skin lesions.– Available now on the AISight® Image Management System (IMS), this research tool automates specimen orientation and identification, enabling pathologists to review samples more efficiently and accurately.PathAssist Derm CapabilitiesPathAssist Derm is the latest addition to PathAI’s suite of AI-powered solutions available on the AISight® IMS. This comprehensive platform provides pathologists with a range of tools to streamline their workflows and improve diagnostic accuracy. PathAssist Derm offers several key capabilities:Automated Specimen Orientation: Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors.Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors. Lesion Identification: Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research.Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research. Detailed Measurements: Provides precise measurements of lesion size and characteristics, facilitating quantitative analysis.“Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone,” said Andrew Beck, Co-Founder & CEO of PathAI. “These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms

Hit Consultant
Jan 23rd, 2025
Pathai Partners To Deploy First Ai-Powered Biospecimen Solutions

What You Should Know:– PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.– This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.Transforming Pathology Workflow: PathAI and Discovery Life Sciences Partner to Advance Precision MedicinePathAI and Discovery Life Sciences have entered a strategic partnership to integrate PathAI’s AISight® Image Management System (IMS), ArtifactDetect, and TumorDetect products into Discovery’s global biospecimens business. This collaboration aims to revolutionize traditional pathology workflows by automating routine tasks, enabling pathologists to dedicate more time to complex analyses, and empowering Discovery’s customers with enhanced tissue-level quantitative insights.Key Highlights of the Partnership:Automation of Pathology Workflows: PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency.PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency. Enhanced Data Quality: Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs.Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs. Custom AI-Driven Solutions: The partnership includes the development of a proprietary AI-driven tissue analysis panel exclusive to Discovery, advancing translational research and biomarker discovery for biopharma partners.Expanding AI-Driven InnovationsThis partnership extends beyond Discovery’s biospecimens business to include potential applications within Discovery’s Specialty Lab Services. These AI-driven solutions are expected to accelerate drug development and precision medicine by providing advanced insights for biopharma research initiatives.Advancing Precision Medicine and DiagnosticsWith increasing investments in immuno-oncology and antibody-drug conjugates, the demand for precise diagnostic tools that optimize patient selection continues to grow. By combining PathAI’s cutting-edge technology with Discovery’s structured, multi-modal datasets, the partnership aims to:Accelerate the development of new assays and diagnostic tools.Enhance the reliability and speed of biomarker discovery.Improve patient outcomes through advanced diagnostic precision.Leadership Perspective“Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in pathology assessments, ultimately benefiting their customers with enhanced data quality and insights,” said Andy Beck, CEO of PathAI

Tech.eu
Jan 3rd, 2025
Your Health - Which Way Will Ai Go In 2025?

If 2023 was the year that generative AI came crashing into the world of humans and made everybody fear for their jobs and their futures, 2024 was the year that the narrative changed.The past 12 months have seen astonishing developments in healthcare and while those not engaging with AI will surely lose their jobs, for those who can afford it, AI is going to prolong lives and banish diseases that today damage people’s quality of life.I give it about five years. Hang on until then and while we may not live forever, we will live better and stronger, holding hands with the machines of loving grace.AI is pulsing through diseases like some kind of digital defibrillator. But is AI the angel on our shoulder or the devil in disguise? Will it be Jekyll or Hyde, what has 2025 in store for our health and our outlook on life?AI has already changed healthcare foreverDeepMind’s AlphaFold, the molecular mastermind that cracked protein structures has already turbocharged drug discovery. The result? Incipient therapies for living nightmares such as Alzheimer’s, cancer and rare genetic diseases. What used to take years now takes days to diagnose.AI is already used widely in healthcare. Algorithms are used to predict patients' risk of death or deterioration, to suggest diagnoses or triage patients, to record and summarise visits to save doctors work and to approve insurance claims.The thing about AI in diagnostics is that it doesn’t blink

INACTIVE